ARIXTRA

This brand name is authorized in United States. It is also authorized in Australia, Austria, Brazil, Canada, Croatia, Cyprus, Ecuador, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Japan, Lithuania, Mexico, Netherlands, Poland, Romania, Singapore, Spain, Turkey, UK.

Active ingredients

The drug ARIXTRA contains one active pharmaceutical ingredient (API):

1	Fondaparinux UNII X0Q6N9USOZ - FONDAPARINUX SODIUM
	Fondaparinux is a synthetic and selective inhibitor of activated Factor X (Xa). The antithrombotic activity of fondaparinux is the result of antithrombin III (ATIII) mediated selective inhibition of Factor Xa.
	Read more about Fondaparinux

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ARIXTRA Solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
B01AX05	Fondaparinux	B Blood and blood forming organs → B01 Antithrombotic agents → B01A Antithrombotic agents → B01AX Other antithrombotic agents
Discover more medicines within B01AX05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	8775W
BR	Câmara de Regulação do Mercado de Medicamentos	505618010042717, 505618010042817
CA	Health Products and Food Branch	02245531, 02258056
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	2486-MEE-1216, 6004-MEE-0321
EE	Ravimiamet	1201004, 1201015, 1201026, 1201037, 1201059, 1201060, 1201071, 1201183, 1201194, 1201206, 1201217, 1201228, 1201239, 1276624, 1276635, 1276646, 1276657, 1286153, 1286164, 1286175
ES	Centro de información online de medicamentos de la AEMPS	02206003, 02206003IP, 02206006, 02206011, 02206014
FI	Lääkealan turvallisuus- ja kehittämiskeskus	117836, 402600, 403966, 470471, 585754
FR	Base de données publique des médicaments	61469681, 64683217, 66048056, 67164882
GB	Medicines & Healthcare Products Regulatory Agency	192113, 367622, 367624, 43329, 92056, 92059, 92062
HK	Department of Health Drug Office	50660, 56558
IL	מִשְׂרַד הַבְּרִיאוּת	6155, 6282
JP	医薬品医療機器総合機構	3339400G1029, 3339400G2025, 3339400G3021, 3339400G4028
LT	Valstybinė vaistų kontrolės tarnyba	1027545, 1027546, 1027547, 1027548, 1027549, 1027550, 1027551, 1027552, 1027553, 1027554, 1027555, 1027556, 1027557, 1027558, 1027559, 1027560, 1027561, 1027562, 1027563, 1027564, 1034058, 1034059, 1034060, 1034061, 1034062, 1034063, 1034068, 1034069, 1034070, 1034071, 1034072, 1034073, 1034074, 1034075, 1034076
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	240M2002
NL	Z-Index G-Standaard	14692201
NL	Z-Index G-Standaard, PRK	86444, 86452
PL	Rejestru Produktów Leczniczych	100125744, 100125750, 100136430, 100136446, 100136452
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W67493001, W67493002, W67493003, W67493004, W67493005, W67493006, W67493007, W67494001, W67494002, W67494003, W67494004, W67494005, W67494006, W67494007, W67495001, W67495002, W67495003, W67495004, W67495005, W67495006, W67495007, W67496001, W67496002, W67496003, W67496004, W67496005, W67496006, W67496007, W67497001, W67497002, W67497003, W67497004, W67497005, W67497006, W67497007
SG	Health Sciences Authority	12059P, 13586P, 13587P
TR	İlaç ve Tıbbi Cihaz Kurumu	8699874080250, 8699874080281, 8699874080298
US	FDA, National Drug Code	67457-592, 67457-593, 67457-594, 67457-595